SVCM
MSLE

Saturn V Capital Management’s Satellos Bioscience MSLE Stock Holding History

Saturn V Capital Management’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72M Hold
350,000
– – 0.39% 22
2026
Q1 		$1.97M Buy
+350,000
New +$3.44M 0.36% 21

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Saturn V Capital Management's MSLE Position: Q2 2026 in Review

Saturn V Capital Management held its Satellos Bioscience (MSLE) position steady in Q2 2026 at 350,000 shares worth $2.72M. The position accounts for 0.39% of the portfolio, ranked #22.

Saturn V Capital Management first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Saturn V Capital Management held 350,000 shares of Satellos Bioscience worth $2.72M as of Q2 2026.
  • Saturn V Capital Management left its Satellos Bioscience share count unchanged in Q2 2026.
  • Satellos Bioscience made up 0.39% of Saturn V Capital Management's portfolio in Q2 2026, its #22 holding.
  • Saturn V Capital Management first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.